Next Article in Journal
Use of Dendritic Cell Receptors as Targets for Enhancing Anti-Cancer Immune Responses
Next Article in Special Issue
The ‘Ins and Outs’ of Early Preclinical Models for Brain Tumor Research: Are They Valuable and Have We Been Doing It Wrong?
Previous Article in Journal
Tailoring Ovarian Cancer Treatment: Implications of BRCA1/2 Mutations
Previous Article in Special Issue
Dysregulation of Macropinocytosis Processes in Glioblastomas May Be Exploited to Increase Intracellular Anti-Cancer Drug Levels: The Example of Temozolomide
Open AccessReview

Lentiviral Vectors as Tools for the Study and Treatment of Glioblastoma

Department of Molecular Medicine, University of Padova, 35121 Padova, Italy
Author to whom correspondence should be addressed.
Cancers 2019, 11(3), 417;
Received: 4 February 2019 / Revised: 6 March 2019 / Accepted: 19 March 2019 / Published: 24 March 2019
(This article belongs to the Special Issue Glioblastoma: State of the Art and Future Perspectives)
Glioblastoma (GBM) has the worst prognosis among brain tumors, hence basic biology, preclinical, and clinical studies are necessary to design effective strategies to defeat this disease. Gene transfer vectors derived from the most-studied lentivirus—the Human Immunodeficiency Virus type 1—have wide application in dissecting GBM specific features to identify potential therapeutic targets. Last-generation lentiviruses (LV), highly improved in safety profile and gene transfer capacity, are also largely employed as delivery systems of therapeutic molecules to be employed in gene therapy (GT) approaches. LV were initially used in GT protocols aimed at the expression of suicide factors to induce GBM cell death. Subsequently, LV were adopted to either express small noncoding RNAs to affect different aspects of GBM biology or to overcome the resistance to both chemo- and radiotherapy that easily develop in this tumor after initial therapy. Newer frontiers include adoption of LV for engineering T cells to express chimeric antigen receptors recognizing specific GBM antigens, or for transducing specific cell types that, due to their biological properties, can function as carriers of therapeutic molecules to the cancer mass. Finally, LV allow the setting up of improved animal models crucial for the validation of GBM specific therapies. View Full-Text
Keywords: glioblastoma; lentiviral vectors; gene therapy; animal models glioblastoma; lentiviral vectors; gene therapy; animal models
Show Figures

Figure 1

MDPI and ACS Style

Del Vecchio, C.; Calistri, A.; Parolin, C.; Mucignat-Caretta, C. Lentiviral Vectors as Tools for the Study and Treatment of Glioblastoma. Cancers 2019, 11, 417.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Search more from Scilit
Back to TopTop